We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » WHO Issues Strong Recommendation for Paxlovid, But Slams Pfizer for Lack of Transparency in Dealmaking Regarding the Drug
WHO Issues Strong Recommendation for Paxlovid, But Slams Pfizer for Lack of Transparency in Dealmaking Regarding the Drug
The World Health Organization (WHO) has issued a “strong recommendation” for Pfizer’s oral antiviral Paxlovid for mild and moderate COVID-19 in people at highest risk of hospitalization, such as unvaccinated, older or immunosuppressed patients.